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Virulence factors of Moraxella 
catarrhalis outer membrane 
vesicles are major targets for 
cross-reactive antibodies and have 
adapted during evolution
Daria Augustyniak1, Rafał Seredyński2,3, Siobhán McClean4, Justyna Roszkowiak1,  
Bartosz Roszniowski1, Darren L. Smith  5, Zuzanna Drulis-Kawa1 & Paweł Mackiewicz6
Moraxella catarrhalis is a common human respiratory tract pathogen. Its virulence factors associated 
with whole bacteria or outer membrane vesicles (OMVs) aid infection, colonization and may induce 
specific antibodies. To investigate pathogen-host interactions, we applied integrated bioinformatic 
and immunoproteomic (2D-electrophoresis, immunoblotting, LC-MS/MS) approaches. We showed that 
OMV proteins engaged exclusively in complement evasion and colonization strategies, but not those 
involved in iron transport and metabolism, are major targets for cross-reacting antibodies produced 
against phylogenetically divergent M. catarrhalis strains. The analysis of 31 complete genomes of M. 
catarrhalis and other Moraxella revealed that OMV protein-coding genes belong to 64 orthologous 
groups, five of which are restricted to M. catarrhalis. This species showed a two-fold increase in the 
number of OMV protein-coding genes relative to its ancestors and animal-pathogenic Moraxella. The 
appearance of specific OMV factors and the increase in OMV-associated virulence proteins during M. 
catarrhalis evolution is an interesting example of pathogen adaptation to optimize colonization. This 
precisely targeted cross-reactive immunity against M. catarrhalis may be an important strategy of host 
defences to counteract this phenomenon. We demonstrate that cross-reactivity is closely associated 
with the anti-virulent antibody repertoire which we have linked with adaptation of this pathogen to 
the host.
Moraxella catarrhalis is an important human-restricted pathogen responsible for sinusitis and otitis media in 
children as well as infections of the lower respiratory tract, causing exacerbation of chronic obstructive pulmo-
nary disease in adults1,2. The most promising vaccine candidates against M. catarrhalis have been shown to induce 
protective immunity in pulmonary clearance of the bacteria in animal models3,4. In human studies, the high anti-
body levels against few vaccine candidates were correlated with reduced bacterial carriage5. Nevertheless, there is 
currently no licensed vaccine against M. catarrhalis6. This species is thought to be composed of two distinct lin-
eages, namely the more pathogenic sero-resistant (SR) strains and the less pathogenic sero-sensitive (SS) ones7,8. 
These two groups of strains show separate evolutionary histories and contain a distinct subset of lineage-specific 
genes, 33 and 49, respectively9. Some of the genes unique to the SR lineage are involved in phosphate metabolism 
but others do not have assigned functions. However, most of the characterized virulence factors are present in the 
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core genome of both SR and SS strains. The difference in pathogenicity correlates with the clinical observation 
that most strains isolated from diseased patients possess the sero-resistant features10. The sero-resistant strains 
isolated from different patients are very similar with respect to their virulence, metabolic potential, CRISPR-cas, 
mobile genetic element content, gene content and chromosomal synteny11. The fact that nearly three-quarters of 
the genes are common, including those associated with virulence, indicates that a range of isolates of M. catarrh-
alis may be controlled by vaccination. A potential distinction between the isolates could result from an extremely 
small number of genes or epigenetic phenomena11. Such epigenetic regulation of multiple gene expression via the 
phase-variable DNA methyltransferase (ModM) regulon was recently reported for M. catarrhalis phase varions 
associated with otitis media12.
The mechanisms of colonization and pathogenesis of M. catarrhalis have been extensively studied and many 
virulence factors have been identified to date. The most important virulence strategies involve: (1) evasion of 
complement-mediated killing mainly via interference with regulatory proteins13–15; (2) polyclonal, non-specific B 
cell activation and redirecting of adaptive immunity16; (3) hiding inside lymphoid tissue, which is the main res-
ervoir facilitating the host invasion17; (4) formation of biofilm18,19; and (5) participation in protease-antiprotease 
imbalance20. Some of these strategies can be driven in part by the release of outer membrane vesicles (OMVs), 
which contain several virulence factors facilitating the delivery of periplasmic and outer membrane components 
to the host14,21. Moreover, OMVs can favour pathogen coexistence and colonization after their interaction with 
the other bacterial species22,23.
Many immune-relevant and shared microbial epitopes stimulate the production of intraspecies and interspe-
cies cross-reacting antibodies with high frequency and have cross-protective efficiency24,25.
The major arm of defence against M. catarrhalis relies on antibody-dependent mechanisms6. We have previ-
ously reported that some of them, including bactericidal, opsonophagocytic and adhesion blocking protective 
function, can be driven in vitro by cross-reactive antibodies that primarily recognize outer membrane proteins 
(OMPs)26. To confer an anti-virulent strategy, the antibodies directed against M. catarrhalis may also act in con-
cert with unique humoral mediators such as neuropeptides27. To investigate the nature and basis of our previous 
observations and define the specific profile of OMPs targeted by cross-reactive antibodies, we performed an 
immunoproteomic analysis of OMVs from two clinical strains of M. catarrhalis (Mc6 and Mc8) which differ in 
phenotypic properties, lipooligosaccharide (LOS) type, source of origin26 and belong to distant phylogenetic lin-
eages. Although a comprehensive proteomic analysis of OMVs from one M. catarrhalis RH4 strain was recently 
published28, immunoproteomic studies have not been performed to date. The immunoproteomic analysis of 
OMVs was characterized by 2D-electrophoresis associated with LC/MS mass spectrometry and carried out by 
cross-immunoreactivity experiments. Moreover, we performed extensive bioinformatics analyses of OMV pro-
teins including four newly sequenced and all previously published Moraxella complete genomes to study features 
of these proteins from a genomic and evolutionary perspective with particular emphasis on their role in virulence.
Results
Phylogenetic relationship between the studied genomes. To determine the evolutionary relation-
ships of the newly sequenced genomes (Mc1, Mc5, Mc6, Mc8) in comparison to other M. catarrhalis strains 
(Supplementary Table S1), we performed phylogenetic analyses of 34 complete genomes using alignments of 739 
orthologous groups of proteins (Fig. 1). Trees obtained by different methods show very similar topologies to trees 
based on the presence and absence of the orthologous groups (Supplementary Fig. S1). All M. catarrhalis strains 
create a fully supported monophyletic clade and exclude the four other Moraxella species isolated from animals. 
Apart from two M. catarrhalis strains, 324 MCAT and 304 MCAT, the other strains are very tightly grouped and 
are characterized by minimal divergence in comparison to other studied bacteria. The newly obtained strains, 
are distributed across various branches of the M. catarrhalis phylogenetic tree. Two M. catarrhalis strains, Mc6 
and Mc8, selected for proteomic analysis, are placed in different clades separated by many other lineages, there-
fore representing relatively distant phylogenetic lineages considering intraspecies variations. Furthermore, both 
strains are phenotypically different in LOS type, autoagglutination ability, adherence potency, biofilm formation 
and source of origin as described previously26.
Profiles of immunoreactive OMV proteins from M. catarrhalis strains. The OMV protein profiles 
from the strains Mc6 and Mc8 were compared by 2-D electrophoresis (2D-SDS PAGE). The resulting peptide 
mass fingerprints were analysed using a M. catarrhalis protein data set including 18 proteins. Only minor vari-
ations in the patterns of resolved protein spots between the strains Mc6 and Mc8 were obtained with respect to 
relative concentration, charge and molecular weight of a few proteins (Table 1). Our proteomic studies identified 
ten additional OMV proteins to those already described by Schaar et al. (2011), which display molecular masses 
between 15 and 120 kDa (Supplementary Data S1). They represent different functional groups. Four of them are 
probably involved in binding and transport of iron ions: FbpA, MhuA, LbpB and TbpA. Others are glutamate 
dehydrogenase (GdhA), ubiquitous surface protein UspA1, structural protein (MipA), polyisoprenoid-binding 
periplasmic protein (YceI), molecular chaperone (GroEL) and dihydrolipoamide dehydrogenase (Lpd). With the 
exception of TbpA, identified in Mc6 OMVs (LC-MS/MS: MW 119.4, accession number SQ01_05725, sequence 
coverage 34%, score 1734), nine of them were immunogenic (Table 1).
A pseudogene SQ02_07885 showing similarity to the gene encoding lactoferrin binding protein (LbpB) was 
annotated in the Mc8 genome. Therefore, it has been later rechecked and verified by resequencing of 1.2 kb PCR 
product. The sequence of this truncated gene contains many stop codons and indels which disrupt its potential 
amino acid sequence and cause frame shifts. The first stop codon appears after 2214 nucleotides giving the poten-
tial amino acid product with the length of up to 738 residues. The original amino acid sequence would result in 
906 residues. However, the truncated sequence contains a complete protein domain (pfam01298, Lipoprotein_5, 
Transferrin binding protein-like solute binding protein) present in its full homologues. We confirmed that the 
www.nature.com/scientificreports/
3SCIentIfIC REPORtS |  (2018) 8:4955  | DOI:10.1038/s41598-018-23029-7
shortened protein retains its immunogenic properties. This protein product was identified in immunoblots and 
showed reactions with antisera as shown below.
Immunoblot analysis of OMV proteins reveals a specific pattern of cross-reactivity with anti-
bodies. To study immunoreactive proteins present in OMVs from Mc6 and Mc8 strains, one homologous 
anti-serum and two cross-reactive, serotype-different murine sera were selected. These sera, namely anti-Mc1, 
anti-Mc6 and anti-Mc8 which were raised in response to whole bacteria in order to better mimic the natural 
reaction of the host, showed significant cross-protective bactericidal and anti-adhesive activity in vitro26. The 
characteristics of used antisera is shown in Table 2. The antisera were specific against strains representing separate 
lineages in the phylogenetic tree of M. catarrhalis strains (Fig. 1) and consequently represent a wide phenotypic 
variation within this species. The advantage of studying Moraxella cross-reactivity using mouse sera is connected 
with the fact that all antibodies specific against M. catarrhalis antigens in mouse are produced de novo without 
any interference from pre-existing antibodies.
In immunoproteomic studies, a combination of 2D-gel electrophoresis, western blot analysis and LC-MS/MS 
was performed. The spots that were immunoreactive with the cross-reactive and homologous antibodies were 
matched to the stained reference gel by comparison of their electrophoretic position, size and shape. The most 
immunoreactive proteins spanned a broad range of pI values between 4.5 and 10 and molecular mass from 20 
to 80 kDa. Overall, 24 Mc6 and 27 Mc8 immunoreactive spots were successfully identified by mass spectrome-
try (out of 51 Mc6 and 52 Mc8 immunoreactive spots, respectively), representing 13 and 14 different proteins 
(Table 1). The number of immunoreactive spots in Mc6 and Mc8 was similar when probed with homologous 
antisera, up to 25% lower for more-potent heterologous antisera (anti-Mc6 or anti-Mc8) and up to 70% lower for 
less-potent heterologous antisera (anti-Mc1).
The analyses allowed the identification of a set of common proteins with different functions, mostly classi-
fied as outer membrane proteins, which were recognized by all three antisera used. Several of these immuno-
reactive proteins, including OMP CD were identified from more than one spot, often with the same molecular 
weight but with different pI values. These are likely to represent isoforms of the same protein that retain their 
immunogenicity. The analyses allowed also for an unambiguous identification of several proteins which showed 
Figure 1. Phylogenetic relationships between Moraxella and Acinetobacter genomes. MrBayes tree based on 
the concatenated alignments of sequences from 739 orthologous groups represented 31 Moraxella genomes and 
three members of Acinetobacter genus. The part of tree marked by the grey rectangle is shown on the left in the 
larger scale. Numbers at nodes, in the order shown, correspond to: posterior probabilities estimated in MrBayes 
(MB), support values obtained by the approximate likelihood ratio test based on a Shimodaira-Hasegawa-like 
procedure (Anisimova and Gascuel O. 2006) calculated in morePhyML (mPh) and bootstrap values obtained in 
PhyML (Phb). Values of the posterior probabilities, SH-like branch supports and bootstrap percentages lower 
than 0.50 and 50%, respectively, were omitted or indicated by a dash “−”.
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qualitative and quantitative differences in immunoreactivity. As presented in Figs 2 and 3, the most immunore-
active -cross-reacting proteins showing the highest staining intensities for IgG antibodies seem to be the outer 
membrane proteins involved in bacterial adhesion (OMP CD, UspA1) or complement resistance (UspA1, OMP 
E, OMP CD, OMP J/OlpA/OMP G1b). On the other hand, the predicted proteins involved in iron acquisition 
such as TbpB or LbpB, including the truncated version of LbpB in Mc8, were rather weakly or not recognized 
by cross-reactive antibodies, while their recognition by homologous sera was abundant for the relevant studied 
strain. A similar pattern of reactivity was observed for protein engaged in iron acquisition by hemoglobin utili-
zation such as MhuA. Iron-binding protein CopB gave a variant and strain-dependent pattern of cross-reactivity. 
The lack of cross-reactivity was noticed for periplasmic ferric binding protein FbpA abundantly expressed in Mc8. 
There were also a few proteins predicted to be both cytoplasmic and surface exposed. Among them were Lpd 
and GroEL chaperone which showed moderate immunoreactivity in both strains while probing with anti-Mc6 
or anti-Mc8 sera in heterologous manner. Taken together, the more-potent cross-reactive antisera (anti-Mc6 
or anti-Mc8) recognized 11 different proteins with high or moderate spot intensities, whereas the less potent 
antiserum (anti-Mc1) recognized between 5 and 7 different proteins (depending on the strain used) thus showed 
lower intensities of reactions in general. The original full-length images of 2D-gels and blots can be seen in 
Supplementary Fig. S2.
Protein description and name Functional category1
MW
(kDa)2 Strain
Accession 
number
Sequence 
coverage (%) Score3
Outer membrane protein CD (OMP CD)
Cell envelope biogenesis, outer 
membrane1, cell binding, 
serum resistance
48.3
Mc6 SQ01_01315 23–56 328–1213
Mc8 SQ02_01320 25–44 464–1064
Outer membrane protein E (OMP E)
Lipid metabolism1, fatty acid 
transport,
serum resistance
49.3
Mc6 SQ01_04940 69–71 1473–1720
Mc8 SQ02_04980 45–67 1105–1995
Outer membrane protein (CopB), TonB-
dependent siderophore receptor
Inorganic ion transport and 
metabolism1, serum resistance 82.8
Mc6 SQ01_06490 30–58 1115–2204
Mc8 SQ02_06550 33–50 1260–2019
Ubiquitous surface protein A (UspA1)
Cell division and chromosome 
partitioning1, cell binding, 
serum resistance
93.3
Mc6 SQ01_03435 24–41 596–1011
Mc8 SQ02_03470 22–23 787–782
Outer membrane porin (OMP M35)
Cell envelope biogenesis, outer 
membrane1, transport and 
binding proteins
38.0
Mc6 SQ01_03260 38 533
Mc8 SQ02_03275 78 1286
Transferrin binding protein B (TbpB) transport and binding proteins 76.2
Mc6 SQ01_05710 22–38 884–1140
Mc8 SQ02_05755 21 710
Lactoferrin binding protein (LbpB) Transport and binding proteins 100.1
Mc6 SQ01_07800 10 353
Mc8 SQ02_07885 13 558
Haemoglobin-utilization protein, TonB-
dependent receptor, (MhuA)
Inorganic ion transport and 
metabolism1, transport and 
binding proteins
107.6
Mc6 SQ01_05485 37–40 1422–1460
Mc8 SQ02_05535 ND ND
Structural protein (MipA) Cell envelope biogenesis, outer membrane1 28.6
Mc6 SQ01_04155 53–60 498–577
Mc8 SQ02_04180 75 799
Fe(3+) ABC transporter substrate-
binding protein (FbpA)
Inorganic ion transport and 
metabolism1 35.7
Mc6 SQ01_07425 ND ND
Mc8 SQ02_07515 58–73 849–1080
Molecular chaperone (GroEL) Posttranslational modification, protein turnover, chaperones1 57.4
Mc6 SQ01_02125 ND ND
Mc8 SQ02_02135 60 1721
Dihydrolipoamide dehydrogenase (Lpd) Energy production and conversion1 51.1
Mc6 SQ01_00050 29 737
Mc8 SQ02_00050 46 1204
Hypothetical protein with TPR domain 
(HP Mc4)
General function prediction 
only1 30.1
Mc6 SQ01_03330 46 554
Mc8 SQ02_03345 62 758
Outer membrane beta-barrel protein 
OMPJ)
Cell envelope biogenesis, outer 
membrane1 18.9
Mc6 SQ01_07075 ND ND
Mc8 SQ02_07135 34 246
Polyisoprenoid-binding periplasmic 
protein (YceI)
General function prediction 
only1 21.2
Mc6 SQ01_05855 ND ND
Mc8 SQ02_05915 63 528
Membrane protein (OMP G1b) Cell envelope 26.9
Mc6 SQ01_02650 29 448
Mc8 SQ02_02660 ND ND
Membrane protein, Opa-like protein A 
(OlpA)
Cell envelope biogenesis, outer 
membrane1 23.3
Mc6 SQ01_01010 50 296
Mc8 SQ02_01010 ND ND
Table 1. Immunogenic proteins determined by LC-MS/MS of excised spots found by immunoblotting on 
2DE gels. 1Functional category according to search results of Cluster of Orthologous Groups (COGs); other 
descriptions were taken from various references; 2Theoretical molecular mass was determined by Mascot; 3Score 
ranges represent MS/MS ion scores determined by peptide mass fingerprinting. Only scores deemed to be 
significant by Mascot (p < 0.05) were presented. ND - not done as there was no reactivity observed on blots.
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Due to the size limitations of 2D electrophoresis for the certain high molecular weight (HMW) proteins of M. 
catarrhalis such as Hag/MID or UspA2, their presence in OMVs and their reactivity with antisera were performed 
by classical SDS-PAGE and Western blot. Strong cross-reactivity was only observed for the ~250 kDa HMW anti-
gen (presumably Hag/MID) of Mc6 and Mc8. There was no cross-reactivity for the other HMW protein, which 
was abundantly visible on the gel, with a MW in excess of 300 kDa. OMVs from Mc6 but not Mc8 Moraxella 
strains heated at 37 °C and 100 °C for 10 min showed the presence of this HMW antigen, which indicates the pre-
dicted presence of UspA2 antigen with very high molecular size and a multimeric structure that was not reduced 
by heating at 100 °C29. The results for HMW antigens are presented in Supplementary Fig. S3.
Potential epitopes in OMV proteins subjected to cross-reaction studies. It is interesting to 
hypothesize on the reasons why some proteins were able to react with antisera elicited by different Moraxella 
serotypes while others were not. One could assume that it is related to various level of sequence conservatism 
of these proteins. Proteins with lower sequence divergence should respond to the cross-reactions with greater 
probability and intensity than more divergent ones. Indeed, the homologous proteins involved in strong positive 
cross-reactions were characterized on average by a significantly smaller mean percentage difference between 
their entire sequences (2.85%) than the proteins engaged in weak or no cross-reactions (8.04%), (p-value = 0.04). 
However, the global sequence divergence may not well reflect the variation/conservatism of epitopes responsible 
for the cross-reactivity.
Therefore, we searched the sequences of proteins for potential epitopes using 15 bioinformatic prediction 
methods. As potential epitopes, we selected sites that were recognized by more than half of the approaches. Plots 
showing the prediction of epitope sites along sequences of the studied proteins are presented in the Supplementary 
Fig. S4. Supplementary Data S2 includes the list of individual amino acid residues that were predicted to be 
involved in the epitopes of individual proteins. The fractions of the sites predicted as epitopes were quite variable 
(Supplementary Data S3). Assuming the 50% prediction threshold, the percent of these sites in sequences range 
from 0.4% (Lpd protein from Mc1 and Mc6 strains) to 22.1% (LbpB protein from Mc8 strain). Proteins that 
were not involved in strong cross-reactions had a significantly larger contribution of predicted epitope sites in 
their sequences (on average 9.9 ± 6.2% SD), than the proteins engaged in such cross-reactions (6.1 ± 3.8% SD, 
t-test, p-value = 0.012). The predicted epitope sites of homologous proteins engaged poorly or not at all in strong 
cross-reactions were also characterized on average as having almost twice the percentage differences between 
their sequences (12.9%) as the epitope sites of homologous proteins involved in the cross-reactions (6.8%).
Distribution of OMV proteins in the studied genomes. To study and characterize OMV proteins in 
a more general functional and evolutionary context, we first clustered all protein sequences from four newly 
sequenced and 23 publicly available full genomes of M. catarrhalis as well as four other Moraxella species into ort-
hologous groups (Supplementary Table S2). Three representatives of Acinetobacter (family Moraxellaceae) were 
added as reference genomes because it is the most closely related genus (with the published complete genome) to 
Moraxella. The analyses revealed 4780 orthologous groups represented by at least two of the 34 studied genomes 
and 779 groups had at least one protein in each of the genomes (Supplementary Data S4).
OMV proteins were assumed to be those that were previously identified in proteomic studies by Schaar et al. 
(2011) and by us. Using homology searches, we assigned the OMV proteins to the orthologous groups. These 
proteins were recognized in 64 orthologous groups (Supplementary Data S1), which contained 1995 annotated 
proteins in total from the studied genomes. Among the 64 OMV protein groups, 43 were conserved and present 
in at least one representative of Acinetobacter as well as in M. catarrhalis and other Moraxella species (Fig. 4A), 
while 24 were found in all genomes studied. However, a substantial proportion (25%), i.e. 16 of the OMV protein 
groups were represented only in Moraxella and five OMV protein groups were restricted to M. catarrhalis: IcIR 
(W2387), Lgt1 (W2401), OppB (W2484), cHP Mc10 (W2552) and HP Mc12 (W2666) (Supplementary Data S1). 
Interestingly, no such unique OMV proteins were found in Acinetobacter or in other Moraxella species although 
their genomes encode many unique proteins of other types (Fig. 4B). A likelihood ratio test (G-test) of independ-
ence showed significant differences between the distribution of orthologous group for total and OMV proteins 
(p-value < 2.2E-16).
Serum
Strain Mc6 Strain Mc8
Titer1
Avidity 
index2
Bactericidal 
titer3 Titer1
Avidity 
index1
Bactericidal 
titer3
anti-Mc1 246,254 46 ± 4.2 261 255,242 34 ± 0.7 75
anti-Mc6 2,140,484 79 ± 1.4 607 751,395 53 ± 1.4 317
anti-Mc8 255,290 57 ± 0.7 234 1,001,067 43 ± 2.8 720
pre-immune <500 ND <3 <500 ND <3
Table 2. Characteristics of murine antisera. 1The end-point of IgG ELISA titer against OMVs is defined as 
reciprocal value of the antiserum dilution giving an absorbance of control non-immunized mouse serum 
enlarged by two standard deviations (2 SD). The values are presented as geometric mean titers from two 
independent experiments. 2Avidity was tested by OMVs ELISA elution assay, using a chaotropic agent 1.5 M 
sodium thiocyanate (NaSCN) to disrupt weak antigen-antibody binding. The results are expressed as mean 
avidity index (AI) with SEM where AI = (OD490 with NaSCN/OD490 without NaSCN) × 100. 3The titer was 
defined as the reciprocal value of the highest dilution of antiserum at which ≥50% killing of the target strain 
was observed. The results were published in our previous paper26.
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Figure 2. Immunoproteomic analyses of M. catarrhalis OMV preparations. After 2D-gel electrophoresis OMV 
proteins were visualized by Coomassie staining (A,E). 2D immunoblots probed with homologous antisera 
(B,F), stronger cross-reactive antisera (C,G) and weaker cross-reactive antisera (D,H). Molecular size markers 
are indicated on the left. The exposure times for chemiluminescent substrate were exactly the same for each 
presented blot. Gel and blot images are cropped and brightness/contrast-adjusted for better readability. Original 
images are shown in Supplementary Fig. S2.
Figure 3. Heatmap of immunoreactive spot intensities. Reactivity of murine post-immunization sera with 
OMVs proteins was estimated semi-quantitatively on a quartile scale. Only proteins that reacted with at least 
one antisera are shown.
www.nature.com/scientificreports/
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Forty four OMV protein groups were found in all 27 M. catarrhalis strains and 32 were identified in all 31 
Moraxella strains examined. Homologues to hypothetical protein MCR_0740 were the least represented in the 
genomes because they were found in only 10 M. catarrhalis strains. Genes coding for a phage-related protein 
PmpL and ubiquitous surface protein A UspA1 were subjected to duplication in several M. catarrhalis strains.
Functional categories of OMV proteins. The majority of all identified OMV proteins were grouped into 
three functional categories: (1) Cell wall/membrane/envelope biogenesis, (2) Translation, ribosomal structure and 
biogenesis and (3) Inorganic ion transport and metabolism. Each of these categories contained more than 10% 
OMV proteins. In turn, the functional groups most enriched in the OMV proteins in comparison to non-OMV 
proteins were: Secondary metabolites biosynthesis, transport and catabolism; Cell wall/membrane/envelope bio-
genesis; Cell cycle control, cell division, chromosome partitioning/Cytoskeleton and Extracellular structures. 
They were represented twice as much among OMV proteins than non-OMV proteins (Supplementary Table S3). 
It is also interesting to compare distribution of total proteins into functional categories across M. catarrhalis 
strains infecting human upper respiratory tract and Moraxella isolated from animals (Supplementary Table S4). 
For many categories, the differences between the fractions were statistically significant. The human pathogens had 
over twice as many proteins involved in: Amino acid transport and metabolism; Defence mechanisms; Nucleotide 
transport and metabolism and Coenzyme transport and metabolism.
Changes in content of genes for OMV proteins in the studied genomes. Using the orthologous 
group distribution and the phylogenetic tree of the studied genomes, we estimated sizes of gene content in ances-
tral genomes as well as gains and losses of genes in individual phylogenetic lineages. We compared the results of 
these studies between genes encoding OMV proteins and all other annotated protein sequences (Fig. 5).
The size of the ancestral OMV protein set for the common ancestor of Moraxella and Acinetobacter was 
assessed to be 40 (Fig. 5A). This number remained almost unchanged during the evolution of Acinetobacter 
genomes because they encode currently 40 or 46 such proteins. In contrast, during the evolution of Moraxella, the 
number of genes encoding these proteins continuously increased. Its successively diverging lineages comprised an 
increasing number of these genes: 50 (the common ancestor of M. boevrei and macacae), 54 (the common ances-
tor of M. bovoculi and caprae), 56 (the common ancestor of all M. catarrhalis strains), 61 (the common ancestor 
of M. catarrhalis strains excluding the basal 324 MCAT and 304 MCAT strains). The subsequent increase in this 
gene content resulted in 58 to 67 such genes per genome in M. catarrhalis strains that evolved after separation of 
Figure 4. Distribution of orthologous group for OMV proteins (A) and total proteins (B) found with 
OrthoMCL across three sets of genomes: Acinetobacter, Moraxella catarrhalis and other Moraxella species. The 
group was included if it was represented by at least one genome in the set. The unique proteins not classified into 
groups were also included.
www.nature.com/scientificreports/
8SCIentIfIC REPORtS |  (2018) 8:4955  | DOI:10.1038/s41598-018-23029-7
the 324 MCAT and 304 MCAT strains. Among the evolved genomes, only small fluctuations in the gene content 
has occurred: up to 5 losses (the lineage of 103P14B1) and up to 4 gains (the lineage of 1280B1 strain).
The increase in the number of genes coding for OMV proteins does not seem to be an artefact related to the 
homology searches in the closely related genomes of M. catarrhalis versus the others because the same anal-
ysis performed with all protein-coding genes did not reveal the trend typical of the genes for OMV proteins. 
Furthermore, the whole proteome showed the opposite trend (Fig. 5B). In contrast to the content of genes encod-
ing OMV proteins, ancestors of Moraxella decreased their global protein-coding gene content by almost 600 
genes, whereas Acinetobacter genomes increased their genomes by 665 to 1772 genes in comparison to their 
common ancestor with 2014 genes. Some increase in the global gene content in Moraxella arose much later 
during evolution and rather independently in individual lineages. The most gene-abundant genomes evolved in 
Moraxella isolated from animals (1805 to 2320 genes), while human pathogenic M. catarrhalis strains encode only 
1544 to 1769 proteins.
These trends in gene content alteration are apparent in Fig. 6A, where the numbers of genes for total or OMV 
proteins estimated for ancestral genomes were plotted along the subsequent internal nodes of the phylogenetic 
tree (Fig. 6C). The number of OMV protein genes clearly increased during evolution and reached a stable max-
imum for M. catarrhalis ancestral genomes. Simultaneously, the total number of protein-coding genes rapidly 
dropped and subsequently increased only slightly. As a result of these tendencies, the percentage of OMV proteins 
coded in the ancestral genomes doubled, from about 2% to almost 4% (Fig. 6B).
Since OMV proteins are common antigens, it was interesting to establish if their sequences showed a greater 
variation than other types of proteins. The median percentage difference of the OMV proteins was slightly larger 
than that of the other proteins: 16.2% and 15.4%, respectively.
Discussion
Proteins associated with OMVs are engaged in diverse biological processes enabling infection and colonization 
of host by pathogens. Many of them are important virulence factors enhancing the potential to cause diseases30. 
Our comprehensive computational analyses of 31 complete Moraxella genomes and three representatives of 
Acinetobacter showed that OMV proteins identified in M. catarrhalis are organized in 64 orthologous groups and 
involved in various functions, especially those related to cell membrane and inorganic ion transport. Interestingly, 
we found that M. catarrhalis genomes are significantly enriched in these OMV proteins in comparison to other 
Moraxella species isolated from animals. It indicates that these proteins are not conserved across other taxa and 
have been quite recently acquired by M. catarrhalis. The acquisition of their genes can be associated with the 
emergence of these human-specific pathogens and is confirmed by the leading role of OMV in the increasing 
infectivity, pathogenicity and virulence of these bacteria. It has been documented that proteins incorporated 
in M. catarrhalis OMVs can play a role in complement evasion, epithelial adhesion, redirection of adaptive 
Figure 5. Gains and losses of genes for OMV proteins (A) and all annotated protein sequences (B) during 
evolution of Moraxella and Acinetobacter genomes. The number of gene gains and losses per phylogenetic 
lineage were presented by bars. Ancestral gene contents in genomes were shown by numbers at tree branches 
and the current gene contents were presented by numbers in parenthesis at individual genomes.
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humoral response, beta-lactam antibiotic cleavage and biofilm formation16,23,28,31. On the other hand, the lack 
of OMV enrichment in Moraxella species infecting other mammals could suggest either a major involvement 
of other virulence factors (e.g. cytotoxins or type IV pili in M. bovis and M. bovoculi) or alternatively their lower 
pathogenicity32,33.
Since OMV components in general are strong immunomodulatory antigens, they can significantly influence 
the mammalian immune system21,34 and stimulate it to develop effective cross-protective defence35,36 which in 
turn may influence the outcome of natural infections37,38. Recently, we have reported the wide range of effec-
tor anti-virulent functions fulfilled by cross-reacting antibodies against phenotypically different M. catarrhalis 
clinical strains26. In contrast to the previous proteomic studies on OMVs from RH4 stain of M. catarrhalis28, our 
present approach, focused on immunoproteomic analyses, revealed a particular set of antigens associated with 
virulence and cross-immunity that showed a similar pattern of responsiveness. The antigens that were highly 
Figure 6. Changes in gene content during evolution of Moraxella and Acinetobacter genomes. Number of genes 
for total proteins and OMV proteins estimated for ancestral genomes (A) in subsequent internal nodes from 1 
to 8 in the phylogenetic tree presented in (C). Percentage of OMV proteins coded in the ancestral genomes from 
subsequent internal nodes (B).
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cross-recognized by sera including OMPCD, UspA1, OMPE, OlpA/OmpJ and presumably Hag/MID, were spe-
cific proteins responsible for serum resistance/complement evasion and/or adhesion enhancement. Therefore, 
the basis of antibody-mediated action directed against heterologous M. catarrhalis strains seems to be multidi-
rectional blocking of these pivotal virulence factors. The observed significant response of cross-reacting anti-
bodies to cytosolic/surface exposed Lpd and in part also to GroEL chaperone seems to be in line with this, as it 
reveals quite potent immunogenic properties of proteins whose virulent potential is well described. To our knowl-
edge, this is the first study showing the immunogenicity of Lpd. In addition, the involvement of Pseudomonas 
Lpd in inhibition of complement cascade has been demonstrated39. GroEL immunoreactivity was observed in 
Burkholderia40 infections. Likewise, the immunogenicity and protective efficacy of GroEL was confirmed for 
Streptococcus pneumoniae against a lethal infection in mice41. Although the surface exposition of GroEL and Lpd 
have not been directly confirmed to date for M. catarrhalis, their presence on the surface of other bacteria includ-
ing Neisseria meningitides42 and Pseudomonas aeruginosa43 suggests a similar location. We were not able to detect 
UspA2 protein involved in serum resistance on blots, despite the confirmed presence of a heat-resistant HMW 
protein (size exceeds 300 kDa on the gel) at least for Mc6. Its identify is implied due to it being highly resistant to 
boiling, a biochemical feature of UspA2. The lack of immunoreactivity for UspA2 may be a result of phase varia-
tion29 or poor transfer to blotting membranes as in case of other bacterial HMW proteins44.
The apparent presence of specific cross-reactive patterns (the qualitative cross-reactive threshold) was 
next confirmed for a distinct group of abundantly expressed OMV antigens, involved in iron acquisition from 
Fe-sequestering host proteins. This group contained protein antigens which did not appear to be classified as 
pivotal virulence factors and were not recognized, or only weakly recognized, by cross-reacting antibodies. 
Interestingly, three of them, namely transferrin-binding protein (TbpB) and lactoferrin-binding protein (LbpB), 
as well as CopB (responsible for binding of both transferrin and lactoferrin) which gave strong homologous reac-
tion in our study, have been reported to induce an antibody response in convalescent sera or sputum1,45. It sup-
ports their specific rather than cross-reactive recognition. We found no reactivity with TbpA and LbpA proteins 
encoded by two Moraxella strains. There is still no conclusive evidence for antibody against M. catarrhalis TbpA 
or LbpA in convalescent phase sera45, although such results exist for experimental meningococcal infection46. The 
inefficiency in TbpA refolding during the electroblotting procedure also cannot be ruled out. For others such as 
hemoglobin-binding protein (MhuA)47 or FbpA, responsible for iron transport from periplasmic space into the 
cell interior48, there is no data on their immunogenic significance to our knowledge. Although, the induction of 
functional neisserial anti-FbpA antibodies in an animal model has been described49, their bactericidal impor-
tance has not been confirmed50.
We found that epitope sequences of homologous non-virulent OMV proteins showing either weak or no 
cross-reactivity were more variable than those of virulent proteins involved in the strong cross-reactions. It clari-
fies why antibodies prepared on one strain cross-reacted with the other strain, most probably with the conserved 
epitopes. Therefore the quantitative increase in OMV protein content during evolution observed in this study 
could compensate the lack of any qualitative changes expressed by conservatism at the sequence level of many 
protein epitopes. Lack, or presence, of cross-reactivity may be due to amino acid replacements or deletions/
insertions in the sequences. For example, we found sites in the sequence of TbpB proteins that are well recog-
nized as epitopes in Mc6 strain by 11 and 12 methods but in strains Mc1 and Mc8 by much smaller number of 
the methods (Supplementary Fig. S5). The difference in the prediction is associated with substantial changes in 
their sequences. Consistent with this, the proteins from the Mc6 strain showed practically no cross-reactivity 
with antisera prepared from the Mc1 or Mc8 strains. However, mutations cannot explain the complete variation 
in cross-reactivity, because a few proteins that have identical sequences were not recognized by the cross-reactive 
antibodies, e.g. FbpA from Mc1 and Mc8 strains, GroEL from Mc1 and Mc6 strains and OMP M35 from all three 
strains. This observation implies than other factors can influence the cross-reactivity, e.g. posttranslational mod-
ifications, different exposition of protein in OMVs, intrinsic features of antigenic epitope such as its accessibility 
and density or at least insufficient levels of certain cross-reactive antibodies51–53.
Taken together, the majority of cross-reactive antibodies was directed against several M. catarrhalis targets 
that are involved in serum resistance and/or promotion of bacterial attachment and as such contribute to the 
pathogenicity of bacteria. It is also difficult to judge their individual importance in vivo. The advantage for the 
host in having antibodies with a range of specificities against bacterial antigens associated with serum resist-
ance is to facilitate an effective defence even if particular sets of (monovalent) antibodies are not present in the 
antiserum.
In conclusion, the cross-reactive humoral immune response elicited by the whole bacteria is directed 
against M. catarrhalis antigens engaged exclusively in complement evasion and colonization/invasion strate-
gies but not those which participate in nutrient or compound acquisition. Despite the fact that strain-specific 
immune responses are a hallmark of many bacterial infections including those caused by M. catarrhalis54, the 
immunity based on cross-reacting anti-virulent activity of antibodies26 is likely to be an additional source of 
defence, which increases the likelihood of successful eradication of this human pathogen. The significant pattern 
of cross-reactivity against pivotal virulence targets is therefore advantageous for the host. On the other hand, 
cross-reactive immunity may have also significant evolutionary implications for bacteria virulence strategies. The 
observed twofold rise in the number of specific OMV proteins during evolution of M. catarrhalis is an interesting 
example of pathogen adaptation in successful colonization of the host and increasing virulence of this species. 
Our findings suggest that virulence factors associated with OMVs and cross-reactive antibodies are pivotal com-
ponents of M. catarrhalis-host interaction and may have implications in the host-pathogen interplay. Further in 
vivo studies are needed to confirm the role of M. catarrhalis OMVs in cross-protection.
Limitations of the data. The conclusions of our study are based on results performed with murine anti-
sera developed to antigens of whole bacteria and with previously documented in vitro protective capacity with 
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human cells. The immmunoproteomic component of our study is therefore based on common physicochemical 
features shared by all protein surfaces including those engaged in antigen-antibody interactions. Furthermore, the 
advantage of studying Moraxella cross-reactivity using mouse sera is connected with the fact that all antibodies 
specific against M. catarrhalis antigens in mouse are produced de novo without any interference from pre-existing 
antibodies. Nevertheless, since M. catarrhalis is a human specific pathogen, limitations of the mouse models have 
to be taken into account. In this context the relevance of our study to natural infections of human host should be 
confirmed in order to verify that our observed results mimic the human host response.
Material and Methods
Reagents. Acetonitrile (Sigma), Antibodies: peroxidase (HRP)-conjugated affinity pure goat anti-mouse 
IgG Fcγ-specific, (Jackson ImmunoResearch); bovine serum albumin BSA (SERVA); Immobilon Western 
Chemiluminescent HRP Substrate (EMD Millipore Inc.), sodium thiocyanate NaSCN (Sigma); sequencing grade 
modified porcine trypsin (Promega), TMB substrate reagent (R&D).
Bacterial strains and culture. Two M. catarrhalis strains were used in the experimental studies: Mc6 and 
Mc8. The bacterial strains were routinely cultivated in BHI (brain heart infusion) broth at 37 °C with orbital shak-
ing (150 rpm) and their characteristics were described previously26.
Outer membrane vesicles isolation. Outer membrane vesicles (OMVs) were isolated according to Schaar 
et al.28 with some modifications. Briefly, 18 h cultures of M. catarrhalis strains were diluted 50-fold in 500 ml Brain 
Heart Infusion (BHI) media and incubated at 37 °C for 16–18 h, shaking (150 rpm). The cultures were harvested 
by centrifugation (8000 rpm for 15 min at 4 °C). The supernatants were collected and passed through 0.22 µm pore 
size filter vacuum pump (Merck, Millipore). The filtrates were concentrated using 50 kDa Vivaspin centrifugal 
concentrators (Amicon ultra, Millipore) at 5000 × g for 30 min at 4 °C. The concentrated supernatants were sub-
sequently pelleted overnight (100 000 × g, at 4 °C) in an ultracentrifuge (Beckman Coulter Optima). The pellets 
containing OMVs were re-suspended in 500 µl of sterile PBS buffer (pH 7.4), aliquoted and stored in −20 °C. The 
sterility of the OMV preparations was confirmed on BHI agar. The protein concentrations in OMVs preparations 
were measured using Qubit fluorimeter or Bradford assay (Sigma-Aldrich Inc.) and the quality of OMVs prepa-
rations was confirmed in 12% SDS-PAGE.
2-D gel electrophoresis of OMV proteins. Two-dimensional electrophoresis (2-DE) procedure was car-
ried out as previously described40. Samples were solubilized in rehydration solution (8 M urea, 2 M thiourea, 4% 
(w/v) CHAPS, 1% (v/v) Triton X-100, 10 mM Tris, 65 mM DTT, 0.8% (v/v) IPG buffer (pH 3-11, GE Healthcare 
Inc.), 0.01% (w/v) bromophenol blue) to the final protein concentration of 1 mg/ml. IPG strips (7 cm, pH 3-11NL, 
GE Healthcare Inc.) were saturated overnight with 120 µl of this solution and subjected to isoelectric focusing in 
a GE Healthcare Ettan IPGphor 3 Isoelectric Focusing Unit (3 hours, total voltage of 7000 V). Subsequently, IPG 
strips were equilibrated for 20 minutes in reducing buffer (6 M urea, 50 mM Tris, 30% (v/v) glycerol, 2% (w/v) 
SDS, 2% (w/v) DTT) followed by 20 minutes in alkylating buffer (6 M urea, 50 mM Tris, 30% (v/v) glycerol, 2% 
(w/v) SDS, 2,5% (w/v) iodoacetamide). The second dimension was resolved on 12% 1 mm-thick SDS-PAGE mini 
gels, with the separation voltage of 130 V. For each experiment, a set of three or four identical gels was prepared. 
One gel was stained with Page Blue Coomassie staining solution (Fermentas Inc.) according to the manufacturer’s 
instructions. The other gels were prepared for the further immunoblotting.
Immunoblotting. Gels were saturated in transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol) 
for 15 minutes. Proteins were transferred to PVDF membranes with a semi-dry Transphor unit (BioRad Inc.) 
at 330 mA for 50 minutes. PVDF membranes were subsequently blocked with 5% BSA solution in the TBST 
buffer (20 mM Tris-HCl, 150 mM NaCl, 0,05% (v/v) Tween 20, pH 7,5) for 1 hour at room temperature. The blots 
were probed overnight at 4 °C with post-immunized pooled murine antisera: one with homologous antiserum 
and two others with heterologous antisera, diluted 1:60,000 at TBST buffer containing 0.1% BSA. Membranes 
were then washed three times for 5 minutes with TBST buffer, incubated with HRP-conjugated goat anti-mouse 
Fcγ diluted 1: 100,000 in TBST buffer with 0.1% BSA for 1 hour at room temperature and washed again three 
times for 5 minutes with TBST buffer. Chemiluminescent detection was carried out with Immobilon Western 
Chemiluminescent HRP Substrate and exposed to Kodak photographic film. Films were digitized with G:BOX 
imaging system (Syngene Inc.) The signal intensities of individual antigen reactions were compared and scored 
semi-quantitatively as described previously55 with quartile modification. Briefly, the intensity of several spots 
could not be analyzed directly due to their overlapping and notable differences in size. Therefore, we firstly col-
lected the equal sections of the primary images, containing whole spots or the middle parts of the spots (depend-
ing on whether the given spot was smaller or larger than the selected area). The procedure was repeated for any 
sections containing image background, in order to compare and eliminate differences in the overall saturation of 
the photographic films. Subsequently, the intensity of the spot samples was evaluated against the respective sam-
ples of the image background, using Image Studio Lite software (LiCor Inc.). Results were presented as percent 
values relative to the most intense spot.
In gel trypsin digestion for LC MS/MS analysis. Gels were rinsed with HPLC-grade water. Excised 
spots were destained in 100 µl of 100 mM ammonium bicarbonate/acetonitrile solution for 30 minutes at room 
temperature and then washed with 500 µl of neat acetonitrile. Gel pieces were then covered with 10 ng/µl porcine 
trypsin solution in 10 mM ammonium bicarbonate/10% (v/v) acetonitrile and incubated for 2 h on ice followed 
by overnight incubation at 37 °C. After digestion, samples were centrifuged and supernatant aliquots were with-
drawn, and stored at −20 °C until LC MS/MS analysis.
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Identification of immunodominant membrane proteins by cross-reactive antibodies. The gels 
were manually aligned on the top of blots by using selected OMP CD, OMP E and Cop B proteins as landmark 
proteins as they were clearly identified in Coomassie blue stained gels from both two strains. High sequence cov-
erage in mass spectrometry for both the proteins was observed.
Peptide identification by LC MS/MS analysis. The analyses were performed on an Ion Trap LC/MS/
MS spectrometer (Agilent Technologies, Santa Clara, CA USA). The resulting peptide mass fingerprints and LC 
MS/MS fragmentation spectra were identified using the MASCOT (http://www.matrixscience.com) and BLAST 
engines56 searching M. catarrhalis protein databases.
SDS-PAGE and Western blots. For resolution of high molecular weight proteins present in OMVs, the 
6% SDS-PAGE stained with GelCode Blue Stain Reagent (Thermo Scientific, USA). Proteins were transferred at 
20 V overnight at 4 °C to an PVDF membrane (Millipore, USA) using Towbin buffer. The membranes were then 
blocked for 2 h with PBS supplemented with Tween 20 (T-PBS) and 3% BSA (SERVA). After 3 washes with T-PBS, 
the membrane strips were incubated with homologous or heterologous murine antisera in T-PBS-1% BSA for 2 h 
at 37 °C. After subsequent 3 washes, membrane strips were incubated with HRP-conjugated goat anti-mouse IgG 
Fcγ diluted 1, 000 in T-PBS-1% BSA for 2 h at 37 °C. Detection of proteins on blot transfer was carried out using 
substrates: 4-chloro-1-naphthol and perhydrol.
Immunization and preparation of mouse antisera. The antisera were obtained as previously 
described26. Briefly, groups of 5–7 BALB/c mice of approximately equal weight, at 8–10 weeks old were immu-
nized intraperitoneally with heat inactivated M. catarrhalis in saline (5 × 107 cfu dose−1) in 0.1 ml doses, three 
times, at 2-week intervals (on days 0, 14 and 28). Ten days after the last immunization, mice were terminally bled 
through the retro-orbital sinus. Sera from each group immunized with particular immunogen (Mc1, Mc6 or 
Mc8) were pooled, divided and stored in aliquots at −70 °C until use. All experimental protocols were approved 
by the Ethical Review Committee of University of Environmental and Life Sciences of Wroclaw, Poland. This 
study complied with the animal experimentation guidelines of the National Institutes of Health guide for the care 
and use of Laboratory animals (NIH Publications No. 8023, revised 1978).
Quantitative and Avidity ELISA. The relative avidities (AI) of antibodies to the OMV antigens, were 
determined by ELISA as described previously26.
Genome sequencing. Four Moraxella genomes were sequenced using the Illumina MiSeq platform 
(University of Northumbria, UK). A 2*250 bp paired-end library (Nextera XT sample prep) were utilized for each 
sample. The raw data was processed by trimming the library adapter sequences and quality filtering was applied 
using CLC genomics workbench v.7.5 (CLC Bio, Aarhus, Denmark). Quality reads below 0.05, along with reads 
shorter than 100 bp and with 2 or more ambiguities were removed (total values removed for strain: MC1 – 0.06%; 
MC5 – 16.91%, MC6 – 7.55%, MC8 – 0.05%). After trimming and filtering, the data were processed and the reads 
were mapped to the reference genomes. The processed reads were used for de novo assembly. A high-quality draft 
genome was assembled by closing the gaps between the scaffolded contigs of the reference assembly by contig 
stitching with de novo contigs. The four final draft genomes comprised from 3 to 5 contigs were grouped in one 
scaffold each. The final genome assemblies were deposited in GenBank under accession numbers CP010573, 
CP010900, CP010901 and CP010902. Their detailed characteristics is provided in Supplementary Table 1.
The sequence of a pseudogene SQ02_07885 in the Mc8 genome was verified by PCR analysis using the prim-
ers, F: gataagccgtataccgccattcatg, R: ctgtctgagtgttctcttgcgcccag. The obtained 1.2 kb product was resequenced 
(Genomed, Poland).
Preparing sequence data for bioinformatics analysis. Four newly sequenced and all publicly available 
23 full genomes from M. catarrhalis strains as well as four other Moraxella species were included in the bioin-
formatics analysis (Supplementary Table 2). Genomes that were not fully sequenced, assembled or annotated 
were excluded because they would bias the presence and distribution of genes. As an outgroup three represent-
atives of Acinetobacter were selected because they are close relatives to Moraxella, grouped together to family 
Moraxellaceae. The data for these genomes were downloaded from the GenBank database (ftp.ncbi.nlm.nih.gov/
genomes). Their annotated protein sequences were clustered into orthologous groups using a genome-scale algo-
rithm OrthoMCL57 assuming BLAST cut-off for sequence similarity 25% and E-value threshold 10−3.
Phylogenetic relationships between the genomes studied were inferred using concatenated alignments of 
sequences from 739 orthologous groups that were represented by one sequence in each of all 34 genomes. The 
sequences were aligned with a slow and accurate algorithm PSI-Coffee, which combines homology extension and 
consistency based progressive alignment58. Sites appropriate for phylogenetic analyses were selected in Gblocks 
using less stringent criteria59. In the final analyses, the alignment with 235,616 sites was used.
Searching for domains in protein sequences and their classification to functional categories. 
The presence of protein domains in OMV proteins were analyzed by local searches of Conserved Domain Database, 
CDD60 using rpsBLAST assuming E-value < 0.01. Protein sequences from the studied genomes were classified to more 
general functional categories according to Clusters of Orthologous Groups (COGs) being a part of the CDD database.
Inferring phylogenetic relationships based on orthologous sequences. In the construction of 
phylogenetic trees, a Bayesian approach was applied with MrBayes61 and maximum likelihood method in more-
PhyML62 using PhyML63. In the MrBayes analysis, a mixed + Γ + I model of amino acid substitutions was used 
to specify appropriate models across the larger space in the Bayesian MCMC analysis64, avoiding the need for a 
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priori model testing. In this approach, two independent runs starting from random trees, each using eight Markov 
chains were applied. Trees were sampled every 100 generations for 1,000,000 generations. In the final analysis, 
trees from the last 703,000 generations that reached the stationary phase and convergence (i.e. the standard devi-
ation of split frequencies stabilized and was lower than the proposed threshold of 0.01) were selected. The best-fit 
substitution model LG + F + Γ + I found among all 120 candidates in ProtTest65 and the best search algorithm 
NNI + SPR were applied in morePhyML. To assess the significance of the branches, non-parametric bootstrap 
analysis was performed on 1000 replicates in PhyML.
The percentage difference between sequences of OMV proteins and the rest of orthologous groups, as well as 
homologous sequences of proteins and their epitope sites, analyed in cross-reaction studies was calculated using 
ClustalW (Larkin et al. 2007) for alignments obtained in PSI-Coffee. To avoid a bias resulting from the presence 
and absence of proteins in different phylogenetic lineages, only sequences represented in all 34 genomes in the 
comparison of OMV and other orthologous protein groups were analysed.
Inferring phylogenetic relationships based on presence/absence of genes. Phylogenetic relation-
ships were calculated based on the presence and absence of 4780 orthologous groups found by OrthoMCL in least 
two genomes. The presence of some genes only in 28 genomes were also included in the dataset. Two methods 
were applied, Bayesian in MrBayes61 and maximum parsimony in PAUP*66. The characters were considered as 
unordered. In MrBayes approach, the gamma-distributed rate model and two independent runs starting from 
random trees using 4 Markov chains were applied. Trees were sampled every 100 generations for 10,000,000 
generations. In the final analysis, trees from the last 2,716,000 generations that reached the stationary phase and 
convergence were selected. In PAUP*, the final tree was searched from 10 starting trees obtained by stepwise 
addition of characters’ sequences followed by the tree-bisection-reconnection (TBR) branch-swapping algorithm. 
In the non-parametric bootstrap analyses, we assumed 1000 replicates.
Inferring ancestral sizes of gene content. Ancestral sizes of gene content in the genomes as 
well as gene gains and losses per phylogenetic lineage were determined in BadiRate67 under the free rates 
birth-death-and-innovation model and maximum likelihood estimation procedure. Phylogenetic relationships 
were assumed as deduced in the phylogenetic analysis in MrBayes, whereas data about the size of homologous 
protein families in the studied genomes were taken from OrthoMCL results.
Computational prediction of potential epitope sites. Sequences of immunoreactive proteins were 
searched for potential epitopes using 15 predictive approaches: AAP68, BCPred69, BepiPred70, CBTOPE71, 
COBEpro72, FBCPred73, IgPred74, SVMTrip75, as well as BcePred76 based on seven amino acid physico-chemical 
scales, hydrophilicity, flexibility, accessibility, turns, antigenic propensity, exposed residues and polarity. These results 
were summarized by counting the number of times individual sites in the sequences were predicted as an epitope77.
Statistical analyses. Statistical analyses were carried out in R package Statistical significance between 
the numbers of protein sequences in functional categories was estimated using likelihood ratio (G-test) test of 
independence and test of proportions. P-values were corrected with Benjamini–Hochberg procedure for mul-
tiple testing. Differences in contribution of predicted epitope sites in sequences of proteins showing various 
cross-reactivity were analysed in t-test.
Data Availability. The genome sequences of Mc1, Mc5, Mc6 and Mc8 can be found in GenBank under acces-
sion numbers: CP010573, CP010900, CP010901, and CP010902 respectively. Most data generated or analyzed 
during this study are included in this published article (and its Supplementary Information files). Other data 
supporting this study are available from the corresponding author upon reasonable request.
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